With extensive expertise in virology, small molecule and antibody
AbbVie scientists bring decades of experience to the fight.
AbbVie is participating in the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership led by the National Institutes of Health and the Foundation for the NIH (FNIH). The partnership brings together more than a dozen leading biopharmaceutical companies, the U.S. Centers for Disease Control and Prevention, the U.S. Food and Drug Administration and the European Medicines Agency to develop an international strategy for a coordinated research response to the COVID-19 pandemic. Learn more.
COVID R&D Alliance
AbbVie is proud to be part of the COVID R&D Alliance, joining forces with others in the industry to help in the fight against COVID-19. Together we are working to identify, study, and accelerate the most promising therapeutic drug candidates, including the I-SPY clinical trial, to evaluate the efficacy of AbbVie’s cenicriviroc, a chemokine dual-receptor antagonist, in hospitalized COVID-19 patients who require high-flow oxygen.
AbbVie is working with Harbour BioMed, Utrecht University, and Erasmus Medical Center to develop a novel antibody therapeutics to prevent and treat COVID-19. The focus of the collaboration is on advancing the fully human, neutralizing antibody 47D11, which targets the conserved domain of the spike protein of SARS-CoV-2, the virus that causes COVID-19.
AbbVie has initiated a Phase 2 study of ibrutinib in patients with
COVID-19 infection. The goal of this study is to determine
whether ibrutinib can improve patient outcomes by diminishing the
immune response known as the cytokine storm that contributes to the
morbidity and mortality in COVID-19.
Along with industry partners, AbbVie has joined the Innovative
Medicines Initiative’s Corona Accelerated R&D in Europe (CARE)
consortium to support research and discovery of targeted medicines
against COVID-19. Through our internal research and collaborations
with external institutions and academia, we are focused on developing
broadly neutralizing anti-COVID-19 antibodies and small molecule
antivirals, which we will bring into clinical trials as quickly as
Harvard University partnership
AbbVie and Harvard University are launching a $30 million research
alliance to study and develop novel therapies against emergent viral
infections. The specific focus of the collaboration will be on
infections caused by coronaviruses and by viruses that lead to
hemorrhagic fever. Together, AbbVie and Harvard Medical School aim to
rapidly integrate fundamental biology into the preclinical and
clinical development of new therapies for viral diseases that address
a variety of therapeutic modalities.